SNWV

Business Context and Reporting Period

Company: SANUWAVE Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: An emerging global regenerative medicine company developing non-invasive devices using Pulsed Acoustic Cellular Expression (PACE) technology. The company currently has no commercial products in the United States; revenues are derived from CE Marked device sales in Europe. The company is focused on wound healing, orthopedic/spine, plastic/cosmetic, and cardiac applications.

Key Financial Metrics

Cash Flow Summary (Q1 2011):
- Net cash used by operating activities: $(2,022,689)
- Net cash provided by financing activities: $3,900,334 (primarily from option exercises)
- Net increase in cash: $1,888,643

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 76% to $251,753, driven by European sales of the new orthoPACE device introduced in July 2010.
• Expense Reduction:
  • Research and Development (R&D) expenses decreased 31% to $749,299, attributed to the conclusion of patient enrollment and follow-up for the dermaPACE clinical trial in the U.S.
  • General and Administrative (G&A) expenses decreased 14% to $1,382,185, largely due to a $330,822 reduction in non-cash stock-based compensation as prior restricted stock grants fully vested.
  • Depreciation expenses dropped 97% to $6,237, as assets held for sale were fully depreciated in the prior year.
• Net Loss Improvement: Net loss decreased by approximately $811,000 compared to the prior year, resulting in a lower loss per share.

Guidance, Outlook, Risks, and Subsequent Events

Outlook and Guidance:
Management expects operating losses to continue over the next few years as the company funds R&D, clinical trials, and regulatory filings. The company anticipates filing the final module of its Pre-Market Approval (PMA) for dermaPACE with the FDA in Q2 2011, with a potential U.S. launch in early 2012 pending approval.

Subsequent Events (Post-March 31, 2011):

• Private Placement: On April 8, 2011, the company closed a private placement raising gross proceeds of $9,114,927 (net proceeds $8,467,121) through the sale of common stock and warrants.
• Debt-to-Equity Conversion: On April 4, 2011, the company converted $4,413,908 of unpaid principal and interest on related party notes into 1,358,126 shares of common stock and issued additional warrants.

Risks and Contingencies:

• Going Concern: The company has a significant accumulated deficit ($56.5 million) and working capital deficiency. Continued operations depend on future capital contributions or financing.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2011, citing a material weakness in accounting for complex financial instruments and stock-based compensation.
• Legal Proceedings: The company is a defendant in a breach of contract lawsuit seeking over $3 million; management believes the claims are unfounded.
• Regulatory Risk: No assurance can be given regarding the success of clinical trials or the timing of regulatory approvals.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $8.5 million net proceeds from the April 2011 private placement to fund operations through the expected FDA filing and launch timeline.
• Debt Conversion Accounting: Monitor the Q2 2011 financial statements for the accounting treatment of the $4.4 million debt-to-equity conversion and potential impact on earnings.
• Internal Control Remediation: Review progress on the remediation plan for the material weakness in internal controls over financial reporting.
• Regulatory Milestones: Track the submission and FDA response to the final PMA module for dermaPACE expected in Q2 2011.
• Revenue Concentration: Confirm the sustainability of European revenue streams given the lack of U.S. commercial products.